Non-negligible risk of HBV reactivation among rheumatoid arthritis patients receiving JAK inhibitors: bridging the evidence gap.
Lan TY, Lee TJ, Chang TW, Tseng TC, Lai PH, Cheng CF, Kao JH, Lin KY, Pai SY, Wu CH, Wang KY, Lo WY, Huang SC, Shen CY, Lu CH, Yang HC, Hsieh SC, Li KJ.
Lan TY, et al. Among authors: lai ph.
Rheumatology (Oxford). 2025 Aug 6:keaf419. doi: 10.1093/rheumatology/keaf419. Online ahead of print.
Rheumatology (Oxford). 2025.
PMID: 40794751